DexCom, Inc. - Common Stock (DXCM)

Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.

Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.

Dexcom G7 15-Day CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features.

Dexcom stock surged Thursday after the FDA cleared its newest diabetes device for an extended 15-day wear time.

Let’s dig into the relative performance of Masimo (NASDAQ:MASI) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.

Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies navigate potential margin pressures and competitive shifts.

Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers.

Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.

The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we will witness groundbreaking changes that redefine how care is delivered, diseases are treated, and wellness is maintained. Below, we explore ten

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.

Based on a technical and fundamental analysis of NASDAQ:DXCM we ask: Is DEXCOM INC (NASDAQ:DXCM) on the Verge of a Major Breakout as a Strong Growth Stock?

Over the past six months, DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 8% to $74.17 per share. This run-up might have investors contemplating their next move.

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.

Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.

Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest of the patient monitoring stocks fared in Q4.

Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.

The company is facing a regulatory setback. But one analyst doesn't expect that to impact its upcoming, potential approval.